Does ADALIMUMAB Cause Second primary malignancy? 7 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.
7
Reports of Second primary malignancy with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
1
Deaths
6
Hospitalizations
How Dangerous Is Second primary malignancy From ADALIMUMAB?
Of the 7 reports, 1 (14.3%) resulted in death, 6 (85.7%) required hospitalization, and 1 (14.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does ADALIMUMAB Cause?
Drug ineffective (71,926)
Pain (37,514)
Arthralgia (35,592)
Rheumatoid arthritis (29,817)
Fatigue (29,420)
Injection site pain (28,679)
Headache (19,891)
Nausea (19,299)
Rash (18,690)
Pain in extremity (18,319)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ADALIMUMAB Alternatives Have Lower Second primary malignancy Risk?
ADALIMUMAB vs ADALIMUMAB-AACF
ADALIMUMAB vs ADALIMUMAB-AATY
ADALIMUMAB vs ADALIMUMAB-ADAZ
ADALIMUMAB vs ADALIMUMAB-ADBM
ADALIMUMAB vs ADALIMUMAB-AFZB